Background Despite increasing evidence on the bi-directional association between cancer and atherosclerotic cardiovascular disease (ASCVD), less is known about differences in mortality among individuals with co-existing diseases. Objective We examined all-cause and disease-specific mortality among U.S. adults living with cancer, ASCVD, and co-existing cancer and ASCVD. Methods Among adults aged ≥18 years in the National Health Interview Survey (2005-2018) linked to the National Death Index (through December 31, 2019), we estimated multivariable-adjusted HRs (aHRs) and 95% CIs using Cox proportional hazards models. Mortality outcomes were compared across individuals with cancer alone, ASCVD alone, and co-existing conditions, relative to those with neither condition. Results Among 388,632 individuals, 1.3% had co-existing cancer and ASCVD, representing approximately 3.0 million U.S. adults annually. Over a mean follow-up of 7.2 years, co-existing disease was associated with the highest all-cause mortality (aHR, 2.45 [95% CI: 2.23-2.70]), exceeding ASCVD alone (aHR, 1.93 [1.82-2.04]) and cancer alone (aHR, 1.90 [1.77-2.04]). Co-existing disease was associated with elevated risks of both cancer mortality (aHR, 4.18 [3.48-5.03]) and cardiovascular mortality (aHR, 2.73 [2.30-3.24]). Among those living with co-existing diseases, older age (≥75 years) (aHR, 6.02 [1.97-18.37]), diabetes (aHR, 1.23 [1.03-1.46]), and current/former smoking status (aHR, 1.26 [1.07-1.49]) were associated with increased hazards of all-cause mortality. Conclusions Among community-dwelling U.S. adults living with cancer and/or ASCVD, co-existing disease was associated with substantially higher mortality. These findings highlight the elevated burden of mortality among individuals with co-existing cancer and ASCVD and underscore the importance of integrated cardio-oncology care.
Reed Mszar, Leah M. Ferrucci, D. Satti et al.· JACC: Advances· 0 citations
Background Low-density lipoprotein cholesterol (LDL-C) lowering with lipid-lowering therapy (LLT) is foundational for atherosclerotic cardiovascular disease (ASCVD) prevention. Objectives The purpose of this study was to evaluate LDL-C levels and LLT at the time of acute myocardial infarction (AMI). Methods We retrospectively assessed LDL-C levels and LLT use at presentation and discharge among patients hospitalized with AMI from March 2018 to August 2022. Results Among AMI patients with no prior ASCVD diagnosis (n = 1,159), 94.7% had LDL-C ≥55 mg/dL, 86.7% had LDL-C ≥70 mg/dL, and 33.6% were on outpatient statin therapy prior to admission. Among those not taking LLT and aged 18 to 79 years with available risk data, 89.0% met statin eligibility in the 2026 U.S. dyslpidemia guideline. Among AMI patients with prior ASCVD (n = 689), 81.0% had LDL-C ≥55 mg/dL, 64.7% had LDL-C ≥70 mg/dL, 73.7% were previously on statins, and 3.9% were on combination LLT. Although 94.0% of all AMI patients were discharged on statins (81.8% with high intensity), only 5.0% were discharged with combination LLT. Among patients with prior ASCVD and LDL-C ≥55 mg/dL, 24.9% had an increase in statin intensity, 7.2% received combination LLT, and 47.0% received no LLT intensification at discharge. Conclusions In a contemporary AMI cohort, ∼2 in 3 patients presenting with a new ASCVD diagnosis were not previously on a statin, and nearly all had LDL-C ≥55 mg/dL. Among AMI patients with known ASCVD, ∼1 in 4 were not on a statin, and ∼4 in 5 had LDL ≥55 mg/dL. Combination LLT remained low at presentation and discharge despite suboptimal LDL-C, underscoring actionable gaps in ASCVD management.
Mohammed Essa, Qifan Wu, Yuan Lu et al.· JACC: Advances· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.